TITLE

Pharmacogenetically Driven Treatments for Alcoholism

AUTHOR(S)
Arias, Albert J.; Sewell, R. Andrew
PUB. DATE
June 2012
SOURCE
CNS Drugs;2012, Vol. 26 Issue 6, p461
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pharmacogenetic analyses of treatments for alcohol dependence attempt to predict treatment response and side-effect risk for specific medications. We review the literature on pharmacogenetics relevant to alcohol dependence treatment, and describe state-of-the-art methods of pharmacogenetic research in this area. Two main pharmacogenetic study designs predominate: challenge studies and treatment-trial analyses. Medications studied include US FDA-approved naltrexone and acamprosate, both indicated for treating alcohol dependence, as well as several investigational (and off-label) treatments such as sertraline, olanzapine and ondansetron. The best-studied functional genetic variant relevant to alcoholism treatment is rs 1799971, a single-nucleotide polymorphism in exon 1 of the OPRMl gene that encodes the |i-opioid receptor. Evidence from clinical trials suggests that the presence of the variant G allele of rs 1799971 may predict better treatment response to opioid receptor antagonists such as naltrexone. Evidence from clinical trials also suggests that several medications interact pharmacogenetically with variation in genes that encode proteins involved in dopaminergic and serotonergic neurotransmission. Variation in the DRD4 gene, which encodes the dopamine D4 receptor, may predict better response to naltrexone and olanzapine. A polymorphism in the serotonin transporter gene SLC6A4 promoter region appears related to differential treatment response to sertraline depending on the subject's age of onset of alcoholism. Genetic variation in SLC6A4 may also be associated with better treatment response to ondansetron. Initial pharmacogenetic efforts in alcohol research have identified functional variants with potential chnical utihty, but more research is needed to further elucidate the mechanism of these pharmacogenetic interactions and their moderators in order to translate them into clinical practice.
ACCESSION #
77789309

 

Related Articles

  • An Evaluation of the Use of Vivitrol in Drug Courts: Preliminary Results. Crèvecoeur-MacPhail, Desirée A.; Cousins, Sarah J.; Rawson, Richard A. // Offender Programs Report;Nov/Dec2013, Vol. 17 Issue 4, p49 

    The article discusses the effects of alcohol dependence management drug naltrexone, marketed under the name Vivitrol, used in drug courts in the U.S. The author uses the Urge to Drink/Use Scale and takes into consideration medication doses administered, duration of alcohol abuse, and side...

  • Pharmacogenovigilance - An Idea whose Time has Come. Şardaş, S. // Current Pharmacogenomics & Personalized Medicine;2010, Vol. 8 Issue 1, p1 

    The article focuses on the importance of pharmacovigilance, a concept of safety and efficacy pharmaceuticals post-marketing surveillance and medication incidents in adverse drug reactions (ADRs), in Turkey. The author emphasized that pharmacogenomics and pharmacogenetics have become a recognized...

  • Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. Carcas, Antonio J.; Borobia, Alberto M.; Velasco, Marta; Abad-Santos, Francisco; Quintana D¡az, Manuel; Fern ndez-Capit n, Carmen; Ruiz-Gim‚nez, Nuria; Madridano, Olga; Llamas Sillero, Pilar // Trials;2012, Vol. 13 Issue 1, p239 

    Background: Hemorrhagic events are frequent in patients on treatment with antivitamin-K oral anticoagulants due to their narrow therapeutic margin. Studies performed with acenocoumarol have shown the relationship between demographic, clinical and genotypic variants and the response to these...

  • Nalmefene.  // Reactions Weekly;Jul2014, Vol. 1511 Issue 1, p33 

    The article presents a case study of a man who developed psychiatric symptoms after treatment with nalmefene.

  • A Meta-Analysis of Acupuncture Combined with Opioid Receptor Agonists for Treatment of Opiate-Withdrawal Symptoms. Ting-ting Liu; Jie Shi; David Epstein; Yan-ping Bao; Lin Lu // Cellular & Molecular Neurobiology;Jun2009, Vol. 29 Issue 4, p449 

    Abstract  This review extends a prior meta-analysis of acupuncture’s utility for treating opioid detoxification, addressing the efficacy of acupuncture when combined with allopathic therapies. Both English and Chinese databases were searched for randomized trials comparing...

  • Nalmefene: risk of psychiatric symptoms?  // Reactions Weekly;Jul2014, Vol. 1511 Issue 1, p2 

    The article informs that according to the Danish Health and Medicines Authority (DHMA), Nalmefene (Selincro) may be associated with adverse psychiatric reactions.

  • Methylnaltrexone bromide.  // Reactions Weekly;Sep2014, Vol. 1520 Issue 1, p159 

    The article presents a case study of a patient who experienced nausea, flatulence, and dizziness after taking methylnaltrexone bromide for opioid-induced constipation.

  • Nalmefene.  // Reactions Weekly;Feb2015, Vol. 1538 Issue 1, p173 

    The article presents a case study of a 54-year-old woman experienced a dissociative feeling while receiving nalmefene for major depressive disorder with associated anxiety.

  • Opioid Receptor Antagonists in the Treatment of Alcoholism. GUARDIA SERECIGNI, JOSEP // Adicciones;2015, Vol. 27 Issue 3, p214 

    Objectives: On the basis of the recent advances in drug therapy of alcoholism, we conducted a review on opioid receptor antagonist drugs with approved indication for the treatment of alcoholism, such as naltrexone and nalmefene. Methods: We reviewed over 100 publications on peptides and opioid...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics